Real-Life experience with purified cannabidiol treatment for refractory epilepsy: A multicenter retrospective study

Drug-resistant epilepsy (DRE) significantly affects the development and quality of life of children and young adults. To describe the effectiveness and safety of purified cannabidiol (CBD) in children and young adults with DRE. A retrospective analysis of medical records of 139 children and young adults (54.7% female, median age 12.0 years) with DRE treated with purified CBD from 2018-2022 at 5 medical centers in Israel.

Long-term use of cannabidiol-enriched medical cannabis in a prospective cohort of children with drug-resistant developmental and epileptic encephalopathy

We report our findings regarding effectiveness, safety, and tolerability of cannabidiol (CBD)-enriched medical cannabis as add-on therapy in children with drug-resistant epileptic encephalopathies (DEEs) after a median follow-up of 20 months.